Harbin Medisan Pharmaceutical Co Ltd Tangible Net Worth Ratio
Harbin Medisan Pharmaceutical Co Ltd tangible net worth ratio. Harbin Medisan Pharmaceutical Co Ltd (002900) has a Tangible Net Worth Ratio of 90.9% as of September 2025. This metric is calculated by deducting intangible assets (CN¥173.83 Million) from net assets (CN¥1.90 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore how fast is Harbin Medisan Pharmaceutical Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
Tangible net worth ratio of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024. This chart shows how Harbin Medisan Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 13 annual periods from 2012 to 2024. As of September 2025, the ratio stands at 90.9%, reflecting net assets of CN¥1.90 Billion with intangible assets of CN¥173.83 Million CNY. Check 002900 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Harbin Medisan Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2012–2024)
Harbin Medisan Pharmaceutical Co Ltd tangible net worth ratio by year from 2012 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Harbin Medisan Pharmaceutical Co Ltd market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 93.0% | CN¥2.16 Billion | CN¥151.51 Million | CN¥3.80 Billion | ▼ -0.4 pp |
| 2023 | 93.4% | CN¥2.15 Billion | CN¥141.21 Million | CN¥3.44 Billion | ▼ -3.1 pp |
| 2022 | 96.5% | CN¥2.05 Billion | CN¥71.67 Million | CN¥3.28 Billion | ▼ -0.5 pp |
| 2021 | 97.0% | CN¥2.12 Billion | CN¥62.50 Million | CN¥3.07 Billion | ▲ +0.8 pp |
| 2020 | 96.3% | CN¥1.79 Billion | CN¥66.42 Million | CN¥2.48 Billion | ▲ +0.1 pp |
| 2019 | 96.2% | CN¥1.85 Billion | CN¥70.05 Million | CN¥2.67 Billion | ▼ -0.1 pp |
| 2018 | 96.3% | CN¥1.97 Billion | CN¥72.57 Million | CN¥2.51 Billion | ▼ -0.9 pp |
| 2017 | 97.2% | CN¥1.83 Billion | CN¥50.64 Million | CN¥2.18 Billion | ▲ +3.6 pp |
| 2016 | 93.6% | CN¥808.17 Million | CN¥51.76 Million | CN¥1.17 Billion | ▲ +0.8 pp |
| 2015 | 92.8% | CN¥727.97 Million | CN¥52.68 Million | CN¥1.05 Billion | ▲ +1.6 pp |
| 2014 | 91.2% | CN¥609.16 Million | CN¥53.73 Million | CN¥970.46 Million | ▲ +6.1 pp |
| 2013 | 85.0% | CN¥365.13 Million | CN¥54.63 Million | CN¥857.75 Million | ▲ +3.3 pp |
| 2012 | 81.7% | CN¥342.72 Million | CN¥62.61 Million | CN¥719.01 Million | — |